Targeted therapies for the treatment of lung cancerHERBST, Roy S.Seminars in oncology. 2005, Vol 32, Num 6, issn 0093-7754, 46 p., SUP10Conference Proceedings

Targeting key pathways in tumour growth and developmentHERBST, Roy S.British journal of cancer. Supplement. 2005, Vol 92 SUP1, issn 0306-9443, 31 p.Serial Issue

IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancerHERBST, Roy S; WAUN KI HONG.Seminars in oncology. 2002, Vol 29, Num 5, pp 18-30, issn 0093-7754, SUP14Conference Paper

Use of novel second-line targeted therapies in non-small cell lung cancerMASSARELLI, Erminia; HERBST, Roy S.Seminars in oncology. 2006, Vol 33, Num 1, issn 0093-7754, S9-S16, SUP1Article

An update on the role of epidermal growth factor receptor inhibitors in non-small cell lung cancerEDELMAN, Martin J.Seminars in oncology. 2005, Vol 32, Num 6, pp 3-8, issn 0093-7754, 6 p., SUP10Conference Paper

Targeting the epidermal growth factor receptor in non-small cell lung cancerHERBST, Roy S; BUNN, Paul A.Clinical cancer research. 2003, Vol 9, Num 16, pp 5813-5824, issn 1078-0432, 12 p., 1Article

A RAS Renaissance: Emerging Targeted Therapies for KRAS-Mutated Non-Small Cell Lung CancerVASAN, Neil; BOYER, Julie L; HERBST, Roy S et al.Clinical cancer research (Print). 2014, Vol 20, Num 15, pp 3921-3930, issn 1078-0432, 10 p.Article

Angiogenesis as a target for cancer therapyKABAN, Kerim; HERBST, Roy S.Hematology/oncology clinics of North America. 2002, Vol 16, Num 5, issn 0889-8588, vii, 1125-1171 [48 p.]Article

Ongoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populationsJÄNNE, Pasi A.Seminars in oncology. 2005, Vol 32, Num 6, pp 9-15, issn 0093-7754, 7 p., SUP10Conference Paper

Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patientsHERBST, Roy S.Seminars in oncology. 2003, Vol 30, Num 1, pp 30-38, issn 0093-7754, 9 p., SUP1Article

The rationale and potential of combining novel biologic therapies with radiotherapy: Focus on non-small cell lung cancerHERBST, Roy S; O'REILLY, Michael S.Seminars in oncology. 2003, Vol 30, Num 4, pp 113-123, issn 0093-7754, 11 p., SUP9Article

Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: A new paradigm for cancer therapyHERBST, Roy S; SHIN, Dong M.Cancer. 2002, Vol 94, Num 5, pp 1593-1611, issn 0008-543XArticle

Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary resultsZINNER, Ralph G; KIM, Jeri; HERBST, Roy S et al.Lung cancer. 2002, Vol 37, Num 1, pp 17-27, issn 0169-5002Article

Targeted therapy against the epidermal growth factor receptorHERBST, Roy S; WAUN KI HONG.Seminars in oncology. 2002, Vol 29, Num 5, issn 0093-7754, 73 p., SUP14Conference Proceedings

Targeting angiogenesis in lung cancerSANDIER, Alan B.Seminars in oncology. 2005, Vol 32, Num 6, pp 16-22, issn 0093-7754, 7 p., SUP10Conference Paper

Erlotinib (Tarceva): An update on the clinical trial programHERBST, Roy S.Seminars in oncology. 2003, Vol 30, Num 3, pp 34-46, issn 0093-7754, 13 p., SUP7Article

Other compounds and targets in non-small cell lung cancerVILLAFLOR, Victoria; BONOMI, Philip.Seminars in oncology. 2005, Vol 32, Num 6, pp 30-36, issn 0093-7754, 7 p., SUP10Conference Paper

Mode of action of docetaxel - a basis for combination with novel anticancer agentsHERBST, Roy S; KHURI, Fadlo R.Cancer treatment reviews. 2003, Vol 29, Num 5, pp 407-415, issn 0305-7372, 9 p.Article

Companion Diagnostics: Has Their Time Come and Gone?HIRSCH, Fred R; BUNN, Paul A; HERBST, Roy S et al.Clinical cancer research (Print). 2014, Vol 20, Num 17, pp 4422-4424, issn 1078-0432, 3 p.Article

Reports from the 2010 Clinical and Translational Cancer Research Think Tank Meeting: Design Strategies for Personalized Therapy TrialsBERRY, Donald A; HERBST, Roy S; RUBIN, Eric H et al.Clinical cancer research (Print). 2012, Vol 18, Num 3, pp 638-644, issn 1078-0432, 7 p.Article

Current Perspectives and Novel Strategies in the Treatment of Patients With Lung CancerHERBST, Roy S; BUNN, Paul A; JOHNSON, David H et al.Seminars in oncology. 2004, Vol 31, Num 1, issn 0093-7754, 119 p., SUP1Serial Issue

Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibodyNEEDLE, Michael N.Seminars in oncology. 2002, Vol 29, Num 5, pp 55-60, issn 0093-7754, SUP14Conference Paper

New Strategies in Personalized Medicine for Solid Tumors: Molecular Markers and Clinical Trial DesignsJÜRGENSMEIER, Juliane M; EDER, Joseph P; HERBST, Roy S et al.Clinical cancer research (Print). 2014, Vol 20, Num 17, pp 4425-4435, issn 1078-0432, 11 p.Article

Lung CancerHERBST, Roy S; HEYMACH, John V; LIPPMAN, Scott M et al.The New England journal of medicine. 2008, Vol 359, Num 13, pp 1367-1380, issn 0028-4793, 14 p.Article

The role of the epidermal growth factor receptor in the treatment of colorectal carcinomaWAXMAN, Elizabeth S; HERBST, Roy S.Seminars in oncology nursing. 2002, Vol 18, Num 2, pp 20-29, issn 0749-2081, SUP2Article